BioPharmSignal logoBioPharmSignal

Biotech News

Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA

Capricor Therapeutics (CAPR)Capricor TherapeuticsFDA / regulatory

CAPR (CAPR) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is capr.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

CAPRCapricor Therapeutics2026-08-24 13:25 EST

Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA

CAPRCapricor Therapeutics2026-06-26 14:02 EST

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

MNPRMonopar2026-06-30 12:00 EST

Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease

PHVSPharvaris2026-07-06 10:50 EST

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

BIIBBiogen2026-07-13 21:38 EST

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease

AGIOAgios Pharmaceuticals, Inc.2026-07-07 11:00 EST

U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease

BIIBBiogen2026-06-04 11:30 EST

Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

PHARPharming Group2026-06-04 05:00 EST

Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS

ETONEton Pharmaceuticals2026-05-19 20:30 EST

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)

KRYSKrystal Biotech2026-05-18 12:00 EST

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

View all latest news

Capricor Therapeutics

Cell Therapy for Duchenne Muscular Dystrophy Capricor Therapeutics develops deramiocel, an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy. Deramiocel The therapy is designed to address skeletal-muscle and cardiac disease through immunomodulatory, antifibrotic, and regenerative signaling. HOPE-3 Evidence The...

Recent company news

CAPRCapricor Therapeutics2026-08-24 13:25 EST

Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA

CAPRCapricor Therapeutics2026-08-13 20:05 EST

Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

CAPRCapricor Therapeutics2026-08-10 12:30 EST

Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13

CAPRCapricor Therapeutics2026-07-30 13:30 EST

Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel

CAPRCapricor Therapeutics2026-07-29 14:05 EST

The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

Stock data

Close
6.29 USD
Market cap
1.58B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States